PANBELA THERAPEUTICS INC by Panbela Therapeutics, Inc. (PBLA) Stock Price Target 2026

The average analyst price target for PANBELA THERAPEUTICS INC by Panbela Therapeutics, Inc. is $25, 225125.2% above the current price. Of 2 analysts, 1 rates it Buy and 1 Hold. The latest change came on May 16, 2024, when HC Wainwright & Co. downgraded PANBELA THERAPEUTICS INC by Panbela Therapeutics, Inc. from Buy to Neutral.

The Average Analyst Price Target for PANBELA THERAPEUTICS INC by Panbela Therapeutics, Inc. is $25.

Price Target Range — 3 Quarters

Analyst Consensus — 2 Analysts

1Buy

1Hold

Consensus RatingBuy# Analysts2Avg. Consensus PT$25Upside to Avg. PT+225125.2%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for PANBELA THERAPEUTICS INC by Panbela Therapeutics, Inc. Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 15, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—
Jun 24, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—
May 16, 2024	HC Wainwright & Co.	Joseph Pantginis	Downgrade	Buy→Neutral	—
Apr 2, 2024	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$16→$5
Mar 27, 2024	Roth MKM	Jonathan Aschoff	Maintained	Buy	$25
Feb 5, 2024	Roth MKM	Jonathan Aschoff	Maintained	Buy	$500→$25
Dec 18, 2023	Roth MKM	Jonathan Aschoff	Maintained	Buy	$500

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Panbela Therapeutics

HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Panbela Therapeutics

HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Downgrades Panbela Therapeutics to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Panbela Therapeutics (OTC:PBLA) from Buy to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Panbela Therapeutics, Lowers Price Target to $5

HC Wainwright & Co. analyst Joseph Pantginis maintains Panbela Therapeutics (OTC:PBLA) with a Buy and lowers the price target from $16 to $5.

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on Panbela Therapeutics, Maintains $25 Price Target

Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (OTC:PBLA) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
Watching Panbela Therapeutics; Roth MKM Says "'Ipsen FDA Approval Of Onivyde In Pancreatic Cancer And Panbelas Earlier Phase 1/1b Results For Sbp-101 For The Same Indication Gives Investors Reason For Optimism.' Reiterate Buy And $25 Price Target"

Benzinga Newsdesk